BRCA Mutation Risk Underestimated by BRCAPRO Model
More mutations observed than expected at BRCAPRO scores of less than 40%.
More mutations observed than expected at BRCAPRO scores of less than 40%.
Experts voted 13-0 that Roche’s test was safe and effective as first step in cervical cancer screening.
More than one-third of postmenopausal women estimate their risk of ovarian cancer to be at least 50%.
Researchers found a complete response for 94.4% of women with locally advanced cervical cancer treated with erlotinib and cisplatin-based chemoradiation.
Research has revealed new genetic variants in patients with ovarian cancer that may eventually help detect the disease earlier.
Patients given bevacizumab survived almost 4 months longer than controls, but had a higher rate of adverse events.
HPV vaccination is associated with reduced risk of atypic, atypia+ or cervical intraepithelial neoplasia grade 2 or 3.
Oophorectomy reduces the risk of developing ovarian, fallopian tube, or peritoneal cancer by 70% in women with BRCA mutations.
Adjuvant bevacizumab increases overall survival in cervical cancer and improves progression-free survival in glioblastoma.
Millimolar ascorbate induces pro-oxidant effects and boosts chemotherapeutic agents in mouse model.